I’ve been watching the stock market get its butt kicked since January. In the case of ad tech and biotech, the beating began even earlier. I could sum up my posts during this time period as pep rallies with messages like “don’t panic” while attempting to encourage readers to keep buying cheap shares.
Courage: strength in the face of pain or grief.
While most of the market’s share prices got whacked (Nasdaq Composite index is down 24% YTD) there are some really good companies that have experienced shockingly reduced price cuts and are simply too cheap to ignore. These ten are extreme value plays and should be the first to make significant jumps when the correction is over:
Rubius (RUBY) $100M
Puma Biotech (PBYI) $105M
Jounce (JNCE) $197M
fuboTV (FUBO) $618M
DocGo (DCGO) $813M
Nextdoor (KIND) $1.2B
Magnite (MGNI) $1.4B
LiveRamp (RAMP) $1.8B
Digital Turbine (APPS) $2B
Doximity (DOCS) $7.3B
“The opposite of courage is not cowardice; it is conformity. Even a dead fish can go with the flow.” —Jim Hightower